Eligard HCP Template Site

 TRUST IN THE DEPTH OF OUR SUPPORT

Asset 1

Our priority is to support you

and your patients

with ongoing educational events

and patient support materials

Supporting you and your patients

Helps you deliver the best patient care with HCP educational and support services, initiatives and innovations

Go further with patient support

Optimising prostate cancer
patient care
through patient engagement, education, and support

Unlock the full potential of life

Find out more about
our evolving
support in urology
HCP, healthcare professional.

Contact us for more information





    Recordati helps you to deliver
    the best patient care

    With educational and support
    services, initiatives, and innovations

    As a leader in the treatment of urology, Recordati helps to
    advance your development with access to exclusive events,
    bespoke learning experiences and essential resources.

    Click here or scan the QR code to visit
    recordati-urology.info for upcoming

    educational events, congresses
    and comprehensive resources

    Going further for your patients

    introducing-go-beyond

    When men are diagnosed with prostate cancer, they often feel a loss of identity, distress and the need for support

    Recordati offer information, advice & resources to help your patients diagnosed with and treated for prostate cancer

    treatment-logo
    recordati

    Here to support you in urology, continuing to expand and providing therapeutic solutions for:

    Prostate cancer

    Benign prostatic hyperplasia

    Over-active bladder

    Infection-related diseases

    Premature ejaculation & erectile dysfunction

    Product availability may differ by country. Please contact
    your local Recordati representative to find out more.

    References
    1. ELIGARD SmPC. Latest version.

    This website is intended for healthcare professionals only.

     

    ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent
    advanced prostate cancer and for the treatment of high-risk localised and locally
    advanced hormone dependent prostate cancer in combination with radiotherapy.1

    GL-ELIGA-0020 | July 2025 © 2025 Recordati